Page last updated: 2024-12-10

10-[3-(dibutylamino)-2-hydroxypropyl]-9-acridinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

You're describing a compound known as **10-[3-(dibutylamino)-2-hydroxypropyl]-9-acridinone**. This is a complex organic molecule, and here's why it might be important for research:

**Structure and Properties:**

* **Acridinone core:** The base structure of the molecule is acridinone, a heterocyclic compound with a nitrogen atom in a three-ringed system. Acridinones have shown biological activity, especially in relation to DNA interactions.
* **Substituents:** The molecule has a bulky side chain attached at position 10. This side chain contains:
* **Dibutylamino group:** This group provides a basic character and could potentially interact with biological targets.
* **Hydroxypropyl group:** The hydroxyl group (OH) adds polarity to the molecule and might be involved in hydrogen bonding interactions.

**Potential Research Applications:**

Given its structure, this compound might be of interest for research in areas like:

* **Anti-cancer agents:** Acridinones have been explored for their potential as anti-cancer agents due to their ability to interact with DNA. The specific substituents on this molecule could influence its activity against specific cancer cells.
* **Antibacterial agents:** Some acridinones exhibit antimicrobial properties, and the side chain in this compound could modify its activity against various bacteria.
* **Photodynamic therapy:** Acridines can be used as photosensitizers in photodynamic therapy (PDT) to kill cancer cells. The specific substituents on this molecule could impact its ability to absorb light and generate reactive oxygen species.
* **Other biological activities:** The combination of the acridinone core and the side chain substituents could potentially lead to various other biological activities, such as anti-inflammatory, antiviral, or antioxidant effects.

**Important Considerations:**

* **Toxicity:** Any potential use of this compound in biological systems would require extensive toxicological studies to assess its safety.
* **Synthesis and characterization:** The synthesis of this compound might be challenging, and its properties need to be carefully characterized before any further research.
* **Target identification:** Identifying the specific biological targets for this molecule is crucial to understand its mechanism of action and potential therapeutic applications.

**Conclusion:**

10-[3-(dibutylamino)-2-hydroxypropyl]-9-acridinone is a complex molecule with potential for research in various biological fields. However, further studies are necessary to fully understand its properties and potential applications.

Cross-References

ID SourceID
PubMed CID3724061
CHEMBL ID1508993
CHEBI ID117023

Synonyms (13)

Synonym
MLS001030052-02
MLS001030052
10-(3-dibutylamino-2-hydroxy-propyl)-10h-acridin-9-one
smr000427277
CHEBI:117023
AKOS005461420
10-[3-(dibutylamino)-2-hydroxypropyl]acridin-9-one
STK528661
10-[3-(dibutylamino)-2-hydroxypropyl]acridin-9(10h)-one
HMS2778K17
CHEMBL1508993
10-[3-(dibutylamino)-2-hydroxypropyl]-9-acridinone
Q27203647
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
acridines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (11)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency28.18380.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency39.81075.623417.292931.6228AID485281
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency75.11370.100020.879379.4328AID588453; AID588456
TDP1 proteinHomo sapiens (human)Potency29.09290.000811.382244.6684AID686978
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency11.58210.00419.984825.9290AID504444
importin subunit beta-1 isoform 1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency44.66845.804836.130665.1308AID540263
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency12.83210.004611.374133.4983AID624296; AID624297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]